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Th17 cellsTh17 cells are a lineage of CD4+ T helper cells in immune systemwhich differentiate fromnaïve CD4+ T cells and
have demonstrated to play a critical role in the pathogenesis of different autoimmune disorders. miRNAs are a
novel group of non-coding RNAs which participate in post-transcriptional regulation of gene expression mostly
by pairing with 3′UTR of their mRNA targets and inhibition of its translation. It has been demonstrated that
miRNAs function in various cellular processes such as differentiation, proliferation, and apoptosis. By now, several
signaling pathways and their downstream positive and negative regulators involve in Th17 differentiation have
been discovered. Several studies have reported the aberrant miRNA expression proﬁle in patients with autoim-
mune disease called autoimmune-deregulatedmiRNAs. Here, using integrative miRwalk database which assem-
bles the data gathered from ten different bioinformatics databases designed to predict miRNA-target interaction,
we analyzed possible targeting effect of “autoimmune-deregulatedmiRNAs” on prominent positive and negative
regulators of Th17 differentiation. Our resulting mRNA-miRNA network simply nominated several miRNAs with
strong possibility which probably may have inducing (miR-27b, miR-27a, miR-30c, miR-1, and miR-141) or in-
hibitory (miR-20b, miR-93, miR-20a, miR-152, miR-21, and miR-106a) role in Th17 differentiation by targeting
negative or positive regulators of Th17 differentiation, respectively.
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Autoimmune disorders refer to a group of diseases arising due to ab-
errant immune responses against self-antigens. Like immune responses
against foreign antigens, autoimmune responses recruit the samemajor
components of immune system including innate (i.e. macrophage,
neutrophils, monocytes) and adaptive immune cells (such as B cells
and CD4+/CD8+ T cells). These responses against self-antigens
could involve either the whole body or a speciﬁc organ resulting in
systemic or organ-speciﬁc autoimmunity, respectively (Cotsapas
and Haﬂer, 2013; Vyse and Todd, 1996).
T helper 17 (Th17) lineage is a well-known CD4+ T cell lineage
which is characterized by secreting inﬂammatory cytokines such as
IL-17A, IL-17F, IL-22, and IL-21 and also expressing lineage-speciﬁc
transcription factor, RORC. On the other hand, induced-regulatory T
(iTreg) lineage is an anti-inﬂammatory CD4+T cell lineagewhichdiffer-
entiates from the same naïve CD4+ T cells. This lineage participates in
regulation of immune responses through suppressing differentiation
and function of other effector CD4+ T cells such as Th17 cells. In addi-
tion, iTreg cells play a central role in induction of self-antigen tolerance.
ITreg cells are characterized by the expression of master transcription
factor, FOXP3 and secretion of anti-inﬂammatory cytokines including
IL-10 and TGF-β (Chen et al., 2003; Davidson et al., 2007; Burchill
et al., 2008; Yao et al., 2007).
Recently, increasing number of studies have revealed a pathogen-
ic role of Th17 lineage in development or progression of different
organ-speciﬁc autoimmune diseases including, multiple sclerosisFig. 1.Non-metabolic signaling pathways of naïve CD4+T cells differentiation to Th17 lineage n
pathway, and AHR receptor signaling pathway.(MS), rheumatoid artists (RA), psoriasis, systemic lupus erythematosus
(SLE), inﬂammatory bowel disease (IBD), allergy and asthma (Waite
and Skokos, 2011). Accordingly, numerous studies have been carried
out to shed light on the precise molecular mechanisms and signaling
pathways involved in induction of pathogenic Th17 differentiation
and to ﬁnd the best therapeutic targets for the suppression of its differ-
entiation. Furthermore, it is beneﬁcial to ﬁnd therapeutic targets that
induce iTreg differentiation, while suppressing pathogenic Th17 differ-
entiation, since it has been observed that iTreg cells population
decreases during pathogenesis of above-mentioned autoimmune dis-
eases (Afzali et al., 2007). Nevertheless, the ﬁrst step to get to this
goal is to attain a precise and comprehensive knowledge of signaling
pathways andmolecular mechanisms to determine the fate of differen-
tiation to Th17 and/or iTreg lineages.
MicroRNAs are a class of endogenous small (18–22 nucleotide) non-
coding RNA which play a crucial role in regulation of various cellular
processes such as cell cycle, mitosis, apoptosis, differentiation and so
forth (Bartel, 2004). Hence, up/down-regulation of miRNA expression
could result in numerous abnormalities and dysfunction of cellular ac-
tivities (Bartel, 2004; Garzon et al., 2010). Until now, several studies
have reported miRNAs up/down-regulation during pathogenesis of dif-
ferent autoimmune diseases. Interestingly, a number of these miRNAs
have been accounted for differentiation and pathogenesis of Th17
cells. Although, in recent years many studies have been carried out to
decipher the molecular mechanism of Th17 differentiation, little is
known about the precise role of miRNAs in differentiation of Th17
cells. Few studies have investigated the possible role of miRNAs inamely, TCR signaling pathway, retinoic acid receptor signaling pathway, cytokine signaling
Table 1
List of well-known positive and negative regulators of Th17 differentiation.
Positive regulators of Th17
differentiation
Negative regulators of Th17
differentiation
IL17A IFN-γ
IL17F IL4
IL23 IL12
IL23R IL12R
IL6R STAT5a
IL6 STAT5b
IL21 FOXP3
IL22 ETS1
IL21R PPARγ
CCR6 PIAS3
IL1R GFI1
CD161 TCF1
RORC NR2F6
STAT3 T-bet
IRF4 GATA3
Batf STAT1
AHR STAT4
Runx1 STAT6
IKK-α BCL6
NFKBIZ SMAD3
RelB SMAD4
c-maf SMAD2
ROR-α RUNX3
Hif1a SOCS3
RBX1 RXR
Cul1 RAR
SKP1 TSC1
SMAD6 TSC2
SMAD7 FOXO1
Smurf1 FOXO3
Rheb
mTOR
Raptor
MLST8
Fig. 2.Metabolic pathway of Th17 differentiation. This pathway is associated with glucose metabolism in the cells and it involves Hif1-α and AKT/PI3K/mTORC1 pathway.
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shown that miR-326 (Du et al., 2009), miR-301a (Mycko et al., 2012)
and miR-20b (Zhu et al., 2014) play an inductive role in differentiation
and pathogenesis of Th17 cells. Since, each miRNA is capable of regulat-
ing numerous mRNA targets (Selbach et al., 2008), a vast analysis of
miRNA-mRNA interactions should be performed experimentally to val-
idate such targets. These analyses are both troublesome and laborious. It
seems that an integrative computational mRNA-miRNA interaction
analysis is capable to predict most putative target genes and nominate
most reliable miRNAs involved in Th17 differentiation. To date, several
databases for prediction of mRNA-miRNA interactions have been al-
ready established based on different algorithms (Lewis et al., 2003;
Maziere and Enright, 2007). Not surprisingly, the output of such data-
bases are remarkably dissimilar (Xiao et al., 2009; Dweep et al., 2011).
One reliable solution to this problem is to combine all of expression pro-
ﬁles of miRNAs with an integrative computational analysis. Recently,
several integrative prediction databases have been established (Xiao
et al., 2009; Dweep et al., 2011). MiRwalk is one of these databases
that has its own prediction algorithm besides of accessing to the out-
comes of other prediction algorithms as well (Dweep et al., 2011).
We performed an in-silico study to make an integrative computa-
tional mRNA-miRNA interaction analyses on the literature-derived
autoimmune-deregulated miRNAs and mRNAs of Th17 differentiation
regulators. Our goal was to ﬁnd and nominate novel miRNAs with
positive or negative regulatory role in Th17 differentiation.
2. Methods
2.1. Literature mining
In order to perform data mining, a manually shaped approach was
used in which several key words related tomicroRNA expression, auto-
immune diseases and T helper 17 were combined with a validated
methodological ﬁlter, as previously described (Vosa et al., 2013). Sys-
tematic literature mining was carried out for English papers which
were published until August 2014 including PubMed, Web of science,
Science direct and MEDLINE databases. We also incorporated thereference lists of relevant articles and reviews into our searching strate-
gy. However, unpublished results, on-going studies and conference
abstracts were not included in our systematic review.
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Regarding miRNA proﬁle studies in autoimmune diseases, following
criteria were considered: a] Studieswith emphasis on expression proﬁle
of miRNAs in organ speciﬁc autoimmune diseases at which pathogenic
role of Th17 lineage had been observed (including MS, IBD, SLE, Psoria-
sis, Diabetes and RA). b] Studies on body derived specimen (whole
blood, PBMCs, lymphocyte, brain plaque and so forth) in which Th17
cells were detected. No restrictionwas considered regarding the journal
type or patients nationality. Furthermore, datawere extracted according
to operator's experience upon complete evaluation of full-text contents.
2.3. miRNA–mRNA interaction analyses
All miRNA-mRNA prediction analyses were conducted by miRwalk da-
tabase which is an integrative mRNA-miRNA prediction database (http://
www.umm.uni-heidelberg.de/apps/zmf/mirwalk/) (Dweep et al., 2011).
In addition, in order to search for validated interactions by previous
studies, we recruited miRtarbase (http://mirtarbase.mbc.nctu.edu.tw/)
databasewhich provides experimentally validatedmRNA-miRNA inter-
actions from all previously performed studies (Hsu et al., 2011). The
ﬁnal results were visualized in Cytoscape version 3.
3. Results
3.1. Positive and negative regulators of Th17 differentiation
Hitherto, several studies have been conducted to investigate and es-
tablish signaling pathways involved in Th17 differentiation. Therefore,Table 2
List of deregulated microRNAs in various autoimmune diseases.
Disease Methods of miRNA
expression proﬁling
Aberrantly expressed microRNAs
Up-regulation Down-r
MS MicroArray, qRT-PCR miR-485-3p, miR-376a-3p,
miR-1-3p, miR-18b-5p, miR-493-5p,
miR-599-3p, miR-95-3p, miR-193-3p,
miR-148a-3p,miR-497-5p, miR-193a-3p,
miR-200b-3p, miR-486-5p, miR-155-5p,
miR-326-3p,miR-142-3p, miR-146a-5p,
miR-146b-5p, miR-21-5p, miR-199a-3p,
miR-142-5p, miR-200c-3p, miR-130a-3p,
miR-223-3p, miR-22-3p, miR-320-3p,
miR-214-3p, miR-148a-3p, miR-152-3p,
miR-30a-5p, miR-365-3p, miR-9-5p,
miR-95-3p, miR-186-5p, miR-29b-3p,
miR-29c-3p,miR-210-3p, miR-19a-3p,
miR-324-3p, miR-29a-3p, miR-133b-3p,
miR-26a-5p, miR-16-2-3p
miR-27b
miR-7-1
miR-93-
miR-15a
miR-126
SLE MicroArray, qRT-PCR miR-126-3p, miR-21-5p, miR-148a-3p,
miR-7-5p
miR-17-
miR-184
miR-141
*[mir-14
IBD qRT-PCR miR-150-5p, miR-26a-5p, **[miR-126-3p, miR-34a-5p
miR-199a-3p, miR-15a-5p, miR-200c-3p, miR-130a-3
miR-214-3p, miR-181c-5p, miR-152-3p, miR-30a-5p,
miR-106a-5p, miR-29b-3p, miR-29c-3p, miR-19a-3p,
miR-31-5p, miR-125b-5p, miR-30c-5p, miR-215-5p, m
Psoriasis MicroArray, qRT-PCR,
immunohistochemistry
miR-17-5p, miR-142-3p, miR-146a-5p,
miR-146b-5p, miR-21-5p, miR-106a-5p,
miR-20a-5p, miR-31-5p, miR-200a-3p,
miR-141-3p
miR-326-3
miR-125b-
miR-215-5
RA MicroArray, qRT-PCR miR-155-5p, miR-146a-5p,
miR-146b-5p, miR-223-3p,
miR-150-5p, miR-26a-5p
Let-7a-5p
Diabetes Solexa sequencing,
qRT-PCR
miR-326-3p, miR-27a-3p, miR-27b-3p,
miR-148a-3p, miR-152-3p, miR-30a-5p,
miR-210-3p, miR-29a-3p, miR-26a-5p,
miR-200a-3p
miR-21-5p
*microRNAs showed contradicted expression pattern in different studies. In some studies they
**miRNAs which their deregulation were reported without additional explanation for up or dothe most of positive and negative regulators of differentiation to Th17
cells have been characterized so far. Signaling pathways of Th17 differ-
entiation are divided into twomainmetabolic and non-metabolic path-
ways. Non-metabolic pathways include: 1) T-cell receptor (TCR)
signaling pathway 2) Retinoic acid receptor (RAR) signaling pathway
3) cytokine signaling pathways and 4) Aryl hydrocarbon receptor
signaling pathway (Fig. 1). Metabolic pathways comprise hypoxia-
inducible factor1-α (Hif1-α) and AKT/PI3K/mTORC1 pathways (Zhu
and Qian, 2012; Bi and Yang, 2012; Sundrud and Koralov, 2011; Hirota
et al., 2012; Maddur et al., 2012; Gerriets and Rathmell, 2012; Peters
et al., 2011). Combination of all or most of these signaling routes con-
tributes to the induction of Th17 differentiation (Fig. 2). Our literature
mining, led us to a list of 64 genes which were involved in positive or
negative regulation of Th17 differentiation (Table 1). Noticeably, nega-
tive regulators of Th17 differentiation could be considered as positive
inducers of other T helper lineages, especially iTreg lineage.
3.2. Aberrant miRNA expression in autoimmune diseases
Through a comprehensive literature mining of studies related to
miRNA expression proﬁling in different autoimmune diseases, a list of
miRNAswhichhad been reported to bederegulated in autoimmunedis-
eases was prepared (Table 2). Although, in the most cases a consistent
expression was observed for miRNAs in various studies, a number of
miRNAs demonstrated different expression proﬁle which was due to
different methodology for miRNA expression analysis (i.e. real time
PCR, microarray), heterogeneity of the samples (i.e. whole blood,
PBMCs, tissue lesions) and patient's treatment with immunemodulato-
ry drugs. However, in order to narrow down the results as far asReference
egulation
-3p, miR-184-3p, miR-181c-5p, Let-7 g-5p,
-3p, miR-106a-5p, miR-20a-5p,*[Let-7i-5p,
5p, miR-150-5p, miR-34a-5p, miR-27a-3p,
-5p, miR-20b-5p, miR-340-5p,
-3p, miR-17-5p]
(Honardoost et al., 2014; Junker et al.,
2009; Otaegui et al., 2009; Keller et al.,
2009; Cox et al., 2010; Lorenzi et al.,
2012; Haghikia et al., 2012; Fenoglio
et al., 2011; De Santis et al., 2010;
Guerau-de-Arellano et al., 2010, 2011)
5p, miR-142-5p,
-3p, miR-95-3p, miR-186-5p, miR-31-5p,
-3p, miR-197-3p, miR-10a-5p,
2-3p]
(Zhao et al., 2010, 2011; Ding et al.,
2012; Tang et al., 2009; Pan et al., 2010)
, miR-155-5p, miR-146a-5p, miR-21-5p,
p, miR-223-3p, miR-22-3p, miR-320-3p,
miR-20b-5p, miR-9-5p, let-7 g-5p,
miR-324-3p, miR-29a-3p, miR-133b-3p,
iR-7-5p, miR-130b-3p, miR-196a-5p]
(Fasseu et al., 2010; Wu et al., 2010,
2011; Iborra et al., 2012; Paraskevi
et al., 2012; Olaru et al., 2011; Coskun
et al., 2013)
p, miR-22-3p, miR-365-3p, miR-133b-3p,
5p, miR-197-3p, miR-30c-5p, miR-10a-5p,
p
(Sonkoly et al., 2007; Holst et al., 2010;
Gu et al., 2011)
(Fulci et al., 2010; Stanczyk et al., 2008;
Pauley et al., 2008; Xu et al., 2014)
, miR-93-5p (Zampetaki et al., 2010; Guay and
Regazzi, 2013)
showed over expression, while in the other studies showed decrease in their expression.
wn-regulation.
157M.A. Honardoost et al. / Gene 572 (2015) 153–162possible, those miRNAs which were reported in at least two studies
were selected. Finally, 64 deregulatedmiRNAswere selected and subse-
quently used in our in-silico mRNA-miRNA interaction analysis.
3.3. Prediction of mRNA-miRNA interaction of autoimmune-deregulated
miRNAs and Th17 differentiation regulators
Considering Th17 lineage as a common pathogenic CD4+ T cell line-
age in various autoimmune diseases, we proposed a nominated miRNA
could participate in Th17 differentiation with the following criteria:
a) deregulated expression during pathogenesis of autoimmune diseases
and b) targeting of the positive or negative regulators of Th17 lineage.
Accordingly, deregulated miRNAs of autoimmune diseases were consi-
dered to have a positive or negative role in Th17 differentiation. To
examine such possibility, integrative in-silico mRNA-miRNA prediction
analysiswas performed on autoimmune-deregulatedmiRNAs andwell-
known regulators of Th17 lineage. To accomplish this analysis, two
comprehensive lists of Th17 regulators and autoimmune-deregulated
miRNAs were provided (Tables 1 and 2). miRWalk database was
utilized for in-silico miRNA-mRNA prediction analyses (DweepFig. 3.miRNA–mRNA network considering all interactions with PS of 5 and higher. Autoimmu
Th17 differentiation are placed on the right and left inside the circle, respectively. Inhibitory inte
with green edges, whereas red edges stand for inducing interactions (that is interactions betw
strength of each interaction based on its PS.et al., 2011). miRWalk database represents miRNA-mRNA prediction
results of 10 different databases with a score of 1 or 0 for each database
which predicted the interaction or not, respectively. Thus, an overall
prediction score of 10 demonstrates a strong predicted interaction by
all databases (Dweep et al., 2011).
We analyzed 4096 interactions (64miRNA× 64 regulators) ofwhich
1839 interactions were not predicted by any database (prediction score
(PS) = 0); however, 613 interactions were predicted by one database
(PS = 1), 564 interactions by two databases (PS = 2), 225 interactions
by three databases (PS = 3), 267 interactions by four databases (PS =
4), 387 interactions by ﬁve databases (PS = 5), 143 interactions by six
databases (PS = 6), 34 interactions by seven databases (PS = 7), 19
interactions by eight databases (PS = 8) and ﬁnally 5 interactions
acquired prediction score of 9 (PS = 9) (Supplementary Fig. 1). At
the ﬁrst step, to select the strongest candidates, interactions with
PS b 5 were ignored. The rest of interactions were subjected into the
Cytoscape_v3.0.1 software to visualize miRNA–mRNA network of
autoimmune-deregulated miRNA and positive/negative regulators of
Th17 differentiation (Fig. 3). In the next step, to narrow down the stron-
gest candidates, interactions with PS b 6 were removed from thene-deregulated miRNAs are arranged in a circle shape. Positive and negative regulators of
ractions (i.e. interaction betweenmiRNAs and positive regulator of Th17) are represented
een miRNAs and negative regulators of Th17). Gradient color of green or red edges show
able 3
ducing or suppressing candidate miRNAs based on their interaction with regulators of Th17 differentiation.
Category Rank Th17 inducing
miRNAs
Target genes Expression deregulation in
autoimmune disease
Th17 suppressing
miRNAs
Target genes Expression deregulation in
autoimmune disease
Negative regulators
(PS)
Positive regulators
(PS)
Negative regulators
(PS)
Positive regulators
(PS)
Strong 1 miR-27b FOXO1(8), NR2F6(7),
GATA3(7), TSC1(7),
Stat5a(6), RXRA(6),
PPARG(6)
IRF4(6), RunX1(6) – MS (peripheral blood) = down
– Diabetes (serum) = up
miR-20b IL12RB2(6), FOXO1(6 Hif1a(8), SMAD7(8),
STAT3(7), SMAD6(7),
RUNX1(6), IKK-a(6),
RORC(6)
-MS (inactive plaque) = up
-MS(whole blood) = down
- IBD (biopsies) = deregulated
2 miR-27a NR2F6(7), GATA3(7),
TSC1(7), FOXO1(7),
Stat5a(6), RXRA(6)
IRF4(6), RunX1(6) – MS (active plaque) = up
– MS (peripheral blood) = down
– Diabetes (serum) = up
miR-93 SMAD2(7), IL12RB (6 STAT3(8), SMAD7(8),
Hif1a(7), SMAD6(7),
RORC(6), RUNX1(6)
-MS (whole blood) = down
-MS (Treg) = up
- Diabetes (PBMCs) = down
3 miR-30c Socs3(8), RARB (8),
FOXO3(7), BCL6(6),
RARC(6), TSC1(6),
IRF4(6) – Psoriasis (skin lesions) = down
– IBD (biopsies) = deregulated
miR-20a RARB(7), IL12RB2(6)
BCL6(6),
Hif1a(9), SMAD7(8),
STAT3(7), SMAD6(7),
RUNX1(6)
-MS (treg cells) = down
- Psoriasis (skin lesions) = up
4 miR-1 RARB(8), ETS1(7),
PIAS3(6)
– MS (CD4+ T cell) = up miR-152 ETS1(6) IKK-a(7), SKP1(8),
MLST8(6),
-MS (inactive plaques) = up
- Diabetes (serum) = up
- IBD (biopsies) = deregulated
5 miR-141 Stat4(7), RARB(7),
Stat5a(6), Stat5b(6),
Tbet(6), GATA3(6),
TSC1(6)
Rheb (6) – Psoriasis (skin lesions) = up
– Lupus (PBMCs) = down
miR-21 IL12A(6) STAT3(7), SMAD7(8), -MS (active plaque) = up
-MS (PBMCs) = up
- Psoriasis (skin lesions) = up
- Lupus (CD4 T cell) = up
- Lupus (PBMCs) = up
- Diabetes (PBMCs) = down
- IBD (biopsies) = deregulated
6 miR-106a IL12RB(6), TSC1(6) SMAD7(8), STAT3(7),
Hif1a(6)
-MS (whole blood) = down
- Psoriasis (skin lesions) = up
- IBS (biopsies) = deregulated
Moderate 1 miR-223 FOXO3(7), Stat1(6),
FOXO1(6)
– MS (active plaque) = up
– MS (whole blood) = up
– MS (Treg cell) = up
– Psoriasis (skin lesion) = down
– IBD (biopsies) = deregulated
miR-376 NFKBIZ(7), IKK-a(6) -MS (CD4 T cell) = up
2 miR-142-3p FOXO1(7), TSC1(6) – MS (active plaque) = up
– MS (whole blood) = up
– Psoriasis (skin lesion) = up)
– Lupus (PBMC) = down
miR-497 TSC1(7) SMAD7(7), IKK-a(6) -MS (CD4+ Tcell) = up
-MS (Inactive plaque) = up
3 miR-29a/b/c RARB(8), IFNg(6),
IL12B(6)
AHR(6) miR-29a:
– MS (Treg cell) = up
– Diabetes (serum) = up
– IBD (biopsies) = deregulated)
miR-29b:
– MS (CD4+ T cell) = up
– Diabetes (serum) = up
miR-214 TCF1(6), Stat6(6) RBX1(8), IL1R(6),
mTOR(6), MLST8(6),
-MS(active plaque) = up
-MS (inactive plaque) = up
- IBD (biopsies) = deregulated
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,
– IBD (biopsies) = deregulated
miR-29c:
– MS (Treg cell) = up
– IBD (biopsies) = deregulated
4 Let-7i TSC1(7) RORC(6) – MS (whole blood) = down
– MS (Treg) = up
miR-130b RUNX3(6), TSC1(6) SKP1(8), IKK-a(6) - Lupus (PBMCs) = down
- IBD (biopsies) = deregulated
5 miR-19a Socs3(8), Stat5b(6),
Runx3(6),
IL1R(6), Hif1a(6) – MS (Treg cell) = up
– IBD (biopsies) = deregulated
6 miR-15a RARB(7), SMAD3(6),
TSC1(6),
SMAD7(9), IL1R (6) – MS (active plaque) = up
– MS (whole blood) = down
– MS (Treg cell) = up
– IBD (biopsies) = deregulated
Weak 1 miR-9 PIAS3(6), Stat4(6),
BCL6(6), RXRA(6),
TSC1(6), FOXO1(6),
– MS (inactive plaque) = up
– IBD (biopsies) = deregulated
miR-17 Stat3(6), hif1a(6),
SMAD7(6),
-MS (CD4 T cell) = up
-MS (peripheral blood) = down
- Psoriasis (skin lesion) = up
- Lupus (PBMCs) = down
2 miR-155 ETS1(6), RXRA(6),
FOXO3(6)
– MS (active plaque) = up
– RA (PBMCs) = up
– RA (synovium tissue) = up
– RA (IL17 producing T cell) = up
– IBD (biopsies) = deregulated
miR-142-5p IL17f(6), IL-22(6),
AHR (6),
-MS (active plaque) = up
- Lupus (PBMCs) = down
3 miR-150 Stat5b(6), GATA3(6),
Stat4(6)
– RA (PBMCs) = up
– RA (synovium tissue) = up
– RA (IL17 producing T cell) = up
– IBD (biopsies) = up
miR-7 SKP1(6), mTOR(6) - Lupus (PBMCs) = up
- IBD (biopsies) = deregulated
4 miR-10a GATA3(6), BCL6(6),
TSC1(6)
– Psoriasis (skin lesions) = down
– Lupus (PBMCs) = down
miR-197 IL1R(6), IKK-a(6) - Psoriasis (skin lesion) = down
- Lupus (PBMCs) = down
5 miR-200a Tbet(6), GATA3(6),
RARB(6)
Rheb(6) – Psoriasis (skin lesions) = up
– Diabetes (serum) = up
miR-340 SMAD2(6) IL-22(6), RORC(6), -MS (active plaque) = down
-MS (memory CD4 T cell) = up
6 miR-181c ETS1(6), PIAs3(6),
BCL6(6)
SMAD7(9) – MS (active plaque) = down
– MS (CSF) = deregulated
– IBD (biopsies) = deregulated
miR-31 IL12RB2(6), IL1R(6) - Psoriasis (skin lesion) = up
- Lupus (PBMCs) = down
- Lupus (CD4 T cell) = down
- IBD (biopsies) = deregulated
7 miR-200c ETS1(6), SMAD2(6), NFKBIZ (6) – MS (active plaque) = up
– MS (inactive plaque) = up
– IBD (biopsies) = deregulated
8 miR-199a PIAS3(6), RARB(6) Hif1a(6) – MS (active plaque) = up
– IBD (biopsies) = deregulated
9 miR-196a RARB(6), TSC1(6) SMAD6(7) – Lupus (PBMCs) = down
– IBD (biopsies) = deregulated
10 miR-26a SMAD4 (6) RORC (6) – RA (PBMCs) = up
– RA (synovium tissue) = up
– RA (IL17 producing T cell) = up
– Diabetes (serum = up)
– IBD (biopsies = deregulated)
11 miR-200b ETS1(6) NFKBIZ(6) – MS (CD4 T cell) = up
12 miR-324-3p TSC1(6) SMAD7(7) – MS (Treg) = up
– IBD (biopsies) = deregulated
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rized into three groups of strong, moderate and weak candidates ac-
cording to the following criteria with priority order of: a) the number
of strong interactions with target genes. b) the number of inconsistent
interactions with the predicted role of miRNAs and c) the PS of each in-
teraction. However, the deregulated expression direction of miRNAs in
autoimmune disease was not included for this ranking due to the het-
erogeneity of the included studies. This approach led us to identify
high potential miRNAs involved in differentiation of Th17 cells. Final
list of these candidates and their putative targets and deregulated
expression direction of these miRNAs in autoimmune diseases is repre-
sented (Table 3).4. Discussion
In the current study, mRNAs–miRNAs interaction analysis on
autoimmune-deregulated miRNAs and well-known regulators of Th17
differentiation was implemented to explore novel targets of miRNAs
which might play a vital role in Th17 differentiation. Therefore a
network of mRNAs–miRNAs was diagrammed. Based on this network,
several miRNAs were nominated with strong possibility to induce
(miR-27b, miR-27a, miR-30c, miR-1, and miR-141) or inhibit (miR-
20b, miR-93, miR-20a, miR-152, miR-21, and miR-106a) Th17 differen-
tiation through interaction with the negative or positive regulators of
this pathway, respectively. In this approach, several miRNAs were
predicted to be involved which were positioned as moderate or weak
effectors (Table 3).
Among our strongly nominated miRNAs, miR-20b, was ranked at
ﬁrst location in our list. The suppressing role of miR-20b in Th17 differ-
entiation has been recently validated experimentally by Zhu and
colleagues (Zhu et al., 2014). They have represented that miR-20b
is able to ameliorate pathogenesis of experimental autoimmune en-
cephalomyelitis by targeting RoRγt and STAT3 genes (Zhu et al., 2014).
Interestingly, these validated targets were also predicted by our
mRNA–miRNA network with PS of 6 and 7, respectively. Furthermore,
our network predicts other possible aspects of suppressing function of
miR-20b in Th17 differentiation which might be through targeting of
Hif1a (PS = 8), SMAD7 (PS = 7), SMAD6 (PS = 7) or TGF-β signaling
pathways. In addition, recently we reported up-regulation of miR-26a
in RR-MS patients during relapsing phase in comparison with remitting
phase and healthy subjects (Honardoost et al., 2014). We also investi-
gated the possible role of miR-141 and miR-200a in differentiation of
Th17 cells and showed their inducing role in differentiation of Th17
cells (Naghavian et al., 2015),which is consistentwith predicted inducing
role for these miRNAs in our current mRNA-miRNA network. Consistent-
ly, according to the results of miRtar database, several interactions which
were predicted in our networkwith PS ≥ 7 had been previously validated
in other cells and tissues other than Th17 cells (data not shown). Interest-
ingly, deregulated expression levels of some nominated inducing
(miR-1, miR-29a/b/c, miR-19a, miR-150, miR-155, miR-200a, miR-199a,
miR-26a) or suppressing miRNAs (miR-197, miR-130b, miR-20a/b,
miR93) were completely compatible with their predicted role in Th17
differentiation. All of these observations conﬁrm the ﬁdelity and accuracy
of our mRNA-miRNA network in nominating and discovery of miRNAs
which might participate in Th17 differentiation. However, several
discrepancies in our mRNA–miRNA network were evident which
are needed to be addressed more.
Firstly, two other previously validated miRNAs in Th17 differentia-
tion (i.e. miR-326 and miR-301a) were not present in our nominated
miRNA list. miR-301a was excluded from our list as its up/down-
regulation was reported in a singular study. Meanwhile, miR-326 was
also disqualiﬁed as respective PS was not highly scored despite its
potential to suppress several negative regulators of Th17 (SMAD3,
SMAD4, RUNX3, RARC, RXRA. STAT5b, NR2F6). Inductive role of
miR-326 in Th17 differentiation was already reported by of Du et al.(Du et al., 2009). Hence, we concluded despite of the beneﬁcial aspect
of our mRNA–miRNA network to provide neumerous possible results,
it only predicts the most important miRNAs involved in Th17 differen-
tiation program and does not necessarily introduce all miRNAs partici-
pating in differentiation of this lineage.
Secondly, some of nominated miRNAs showed unreliable interac-
tions in their predicted role in Th17 differentiation. For instance, miR-
20b,which suppresses several positive regulators of Th17 differentiation,
was also predicted to have a suppressing role on negative regulators of
Th17 differentiation. Such kinds of discrepancies could be explained by
several studies aiming to discover precise molecular mechanisms of
Th17 differentiation. Recently, Peters et al. have categorized Th17 lineage
in two pathogenic and non-pathogenic types. Pathogenic Th17 cells are
generated in the absence of TGF-β signaling pathway andmostly present
in autoimmune conditions while, non-pathogenic Th17 cells are pro-
duced by induction of TGF-β signaling pathway (Peters et al., 2011).
Considering of this evidence, we concluded that TGF-β signaling path-
way is not necessarily an inducing pathway for Th17 differentiation as
lack of this signaling pathway was apparent in differentiation of patho-
genic Th17 lineage. This fact is arisen by opposite interactionswhich are
relevant to TGF-β signaling pathway in our mRNA–miRNA network
similar to what we reported for miR-26a in our previous study
(Honardoost et al., 2014).
Another explanation for such kinds of discrepancies is provided by a
recent study of Yosef and colleagues (Yosef et al., 2013). They combined
a high-resolution transcriptional time course proﬁling as a novel
method for reconstructing transcriptional network of Th17 differen-
tiation in order to introduce a dynamic regulatory network control-
ling differentiation of this lineage. They deﬁned three distinct
transcriptional phases with discrete gene expression proﬁle during
in vitro differentiation of naïve CD4 T cells into Th17 lineage, speciﬁcally
at early or induction phase (up to 4 h), intermediate phase where
acquiring of phenotype and ampliﬁcation occurs (4–20 h), and ﬁnally
late or stabilization phase which is associated with IL-23 signaling.
Furthermore, they represented that some known negative regulators
of Th17 (such as SOCS3, STAT2, STAT1) are needed to be expressed in
the ﬁrst stage while some positive regulators (including IRF4, SOCS1,
Batf) are expressed in later phases (Yosef et al., 2013). According to
these results, we concluded that Th17 differentiation is a multi-stage
process and a speciﬁc set of positive or even negative regulators are
required to be expressed in each stage in order to achieve functional
Th17 lineage.
Thus, one miRNA could not be considered as an absolute inducer or
suppressor of Th17 differentiation. In fact, to fulﬁll transcriptional re-
quirement in each stage, a collection of several miRNAs are needed to
exert a regulatory role in Th17 differentiation process. This phenome-
non clariﬁes why for a number of miRNAs, both positive and negative
roles are supposed in differentiation of Th17 cells.
Thirdly, beside of those nominated miRNAs which showed
compatible expression direction with their predicted role in Th17
differentiation, few cases miRNAs with incompatible and illogical
expression direction were noticed. Such discordant note could be
due to the heterogeneity of previous miRNA proﬁling studies
which were performed with different samples or methodology
and possible consumption of immune-modulatory responses in
patients.
Notably, our categorization of nominated miRNAs (strong, median,
and weak groups) was only based on bioinformatics criteria. Thus it is
not surprising that further experimental studies reveal a miRNA from
the weak category to exert a crucial role similar to strong miRNAs in
Th17 differentiation.
5. Conclusion
We utilized miRWalk database for integrative computational
mRNA-miRNA interaction prediction aiming to assess interaction of
161M.A. Honardoost et al. / Gene 572 (2015) 153–162autoimmune deregulated miRNAs with well-known regulators of Th17
differentiation. By analyzing of 64 miRNAs and 4096 interactions, a
network of mRNAs-miRNAs interactions was diagrammed which
predicted 11 miRNAs with strong possibility to induce or suppress
Th17 differentiation. These results are preliminary steps to unravel the
novel mRNAs–miRNAs interactions. Obviously, additional in vitro and
in vivo experiments are required to validate these predictions in Th17
differentiation as are currently on going by our colleagues.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gene.2015.08.043.
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